TransMedics Group, Inc. (NASDAQ:TMDX) Receives $122.70 Consensus PT from Analysts

TransMedics Group, Inc. (NASDAQ:TMDX) has earned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $122.70.

A number of equities research analysts have recently commented on TMDX shares. Piper Sandler reduced their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. TD Cowen decreased their price target on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Baird R W raised TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Oppenheimer reaffirmed an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Finally, Canaccord Genuity Group dropped their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th.

Insider Buying and Selling

In related news, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now owns 732 shares in the company, valued at $61,158.60. This represents a 90.22 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total value of $1,144,623.75. Following the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $8,180,642.53. This trade represents a 12.27 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 19,417 shares of company stock worth $2,240,738 in the last ninety days. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

A number of institutional investors and hedge funds have recently bought and sold shares of TMDX. Raymond James & Associates grew its stake in shares of TransMedics Group by 152.4% in the 2nd quarter. Raymond James & Associates now owns 23,444 shares of the company’s stock worth $3,531,000 after acquiring an additional 14,156 shares in the last quarter. HB Wealth Management LLC purchased a new position in TransMedics Group during the second quarter worth about $318,000. F M Investments LLC bought a new stake in TransMedics Group in the 2nd quarter worth about $10,957,000. Principal Financial Group Inc. increased its stake in TransMedics Group by 603.9% in the 2nd quarter. Principal Financial Group Inc. now owns 56,172 shares of the company’s stock valued at $8,461,000 after buying an additional 48,192 shares during the last quarter. Finally, Signaturefd LLC lifted its position in shares of TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after buying an additional 93 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $61.02 on Tuesday. The company has a market capitalization of $2.05 billion, a price-to-earnings ratio of 64.92 and a beta of 2.06. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group has a twelve month low of $59.72 and a twelve month high of $177.37. The stock has a fifty day simple moving average of $81.71 and a 200 day simple moving average of $126.16.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company’s quarterly revenue was up 63.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.12) EPS. Sell-side analysts expect that TransMedics Group will post 1 EPS for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.